Sangui Biotech International Inc (SBH) - Total Assets
Based on the latest financial reports, Sangui Biotech International Inc (SBH) holds total assets worth €89.10K EUR as of March 2023. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sangui Biotech International Inc - Total Assets Trend (2014–2022)
This chart illustrates how Sangui Biotech International Inc's total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Sangui Biotech International Inc - Asset Composition Analysis
Current Asset Composition (June 2022)
Sangui Biotech International Inc's total assets of €89.10K consist of 51.8% current assets and 48.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 23.3% |
| Accounts Receivable | €13.31K | 10.2% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €63.08K | 48.2% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2014–2022)
This chart illustrates how Sangui Biotech International Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sangui Biotech International Inc's current assets represent 51.8% of total assets in 2022, a decrease from 100.0% in 2014.
- Cash Position: Cash and equivalents constituted 23.3% of total assets in 2022, down from 37.7% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is property, plant & equipment at 48.2% of total assets.
Sangui Biotech International Inc Competitors by Total Assets
Key competitors of Sangui Biotech International Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
XIAO FANG ORD A (SHH) EQSW Exp:
SHG:603207
|
China | CN¥1.25 Billion |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩642.17 Billion |
|
Chongkundang
KO:001630
|
Korea | ₩1.60 Trillion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Sangui Biotech International Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.04 | 0.12 | 0.23 |
| Quick Ratio | 0.04 | 0.12 | 0.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-988.12K | €-861.21K | €-351.14K |
Sangui Biotech International Inc - Advanced Valuation Insights
This section examines the relationship between Sangui Biotech International Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 57.49 |
| Latest Market Cap to Assets Ratio | 3.21 |
| Asset Growth Rate (YoY) | -2.5% |
| Total Assets | €130.79K |
| Market Capitalization | $419.80K USD |
Valuation Analysis
Premium Asset Valuation: The market values Sangui Biotech International Inc's assets at a significant premium (3.21x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Sangui Biotech International Inc's assets decreased by 2.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Sangui Biotech International Inc (2014–2022)
The table below shows the annual total assets of Sangui Biotech International Inc from 2014 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-06-30 | €130.79K | -2.49% |
| 2021-06-30 | €134.12K | +7.02% |
| 2020-06-30 | €125.33K | +58.70% |
| 2019-06-30 | €78.97K | -22.60% |
| 2018-06-30 | €102.03K | +8.80% |
| 2017-06-30 | €93.77K | -15.08% |
| 2016-06-30 | €110.42K | -9.57% |
| 2015-06-30 | €122.10K | -53.14% |
| 2014-06-30 | €260.59K | -- |
About Sangui Biotech International Inc
Sangui Biotech International, Inc., through its subsidiaries, engages in the manufacturing and sales of wound treatment and cosmetic products. The company offers artificial oxygen carriers comprising oxygen carrying blood additives and oxygen carrying blood volume substitutes; nano formulations for the regeneration of skin; chitoskin wound pads; Hemospray, a hemoglobin based wound spray; and woun… Read more